Versanis takeout takes Lilly beyond incretins in obesity

Lilly is pushing beyond the incretin pathway in obesity — aiming for greater removal of fat vs. lean mass — through its takeout of Versanis Bio, which could be valued at up to $1.9 billion.

The rapid rise by  Eli Lilly and Co. (NYSE:LLY) to become the biggest pharma by valuation has been driven largely by its positioning as one of the biggest players in the burgeoning obesity market. The anchor of that franchise will be Mounjaro tirzepatide, a GLP-1R/GIP agonist that is approved for Type II diabetes and widely used off label to treat obesity. An FDA decision on the obesity indication is expected by year-end. ...